藍帆醫療(002382.SZ)：2020年度增加向關聯方採購糊樹脂金額不超2.13億元
格隆匯 10 月 16日丨藍帆醫療(002382.SZ)公佈，公司第五屆董事會第七次會議決議，審議並通過了《關於公司及子公司2020年度增加與關聯方日常關聯交易額度的議案》。
1、隨着公司“年產40億支PVC健康防護手套項目”(實際產能可達50億支/年)的全面建成投產，相關原材料使用量有較多增幅；同時部分健康防護手套原材料價格有較大幅度的增長，結合公司及子公司2020年生產經營及發展情況，同意公司及子公司2020年度增加向關聯方山東朗暉石油化學股份有限公司採購糊樹脂金額不超過21337萬元，本次額度增加後2020年糊樹脂總採購金額擬調增至不超過34080萬元。
2、自新冠肺炎疫情爆發以來，國內對醫療及防護手套需求的持續增加，公司及子公司與淄博恆暉商貿有限公司(“恆暉商貿”)的合作力度進一步加大，同意公司及子公司2020年度增加向關聯方恆暉商貿銷售健康防護手套金額不超過70萬元，本次額度增加後2020年健康防護手套總銷售金額擬調增至不超過100萬元。
3、上海博脈安醫療科技有限公司(“上海博脈安”)主要從事醫療科技領域內的技術開發、技術諮詢、技術服務、技術轉讓等業務，上海博脈安與Biosensors Interventional Technologies Pte. Ltd. (“BIT”)發生關聯交易預計主要是向BIT購買BA9藥物進行藥物研究，BIT開展向關聯方上海博脈安銷售產品有利於日常經營業務的持續穩定並且增加企業所得。因此，同意2020年度BIT與上海博脈安計劃發生關聯交易，向其銷售產品金額不超過140萬元。
4、淄博騰越醫療科技有限公司(“淄博騰越”)及全資子公司Tengyue（Singapore）Medical Technology Pte.Ltd (“騰越(新加坡)”)主要從事醫療器械產品的批發及貨物進出口等業務。為了更好地滿足公司及子公司健康防護手套的訂單需求，同意公司及子公司新增向淄博騰越、騰越(新加坡)採購健康防護手套產品，同時向淄博騰越出售原材料，合計金額不超過6,000萬元。
上述關聯交易增加金額總計不超過27547萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
